Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring 2022 Conference
April 05, 2022 16:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022
April 05, 2022 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Named One of 50 Highest Growth Companies in Massachusetts by the Boston Business Journal
March 17, 2022 09:00 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. to Present at the Oppenheimer Healthcare Conference
March 08, 2022 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Guidance
March 01, 2022 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Appoints Michael J. Driscoll, Ed.D. to Board of Directors
February 17, 2022 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February
February 11, 2022 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 1, 2022
February 07, 2022 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Appoints Prathyusha Duraibabu to Board of Directors
November 22, 2021 07:00 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Reports Third Quarter and First Nine Months 2021 Financial Results
November 09, 2021 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...